Loading clinical trials...
Loading clinical trials...
A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
Conditions
Interventions
Pimavanserin
Locations
18
United States
Movement Disorders Center of Arizona
Scottsdale, Arizona, United States
Neurology Center of North Orange County
Fullerton, California, United States
Premier Clinical Research Institute, Inc.
Miami, Florida, United States
Global Health Research Center, Inc.
Miami Lakes, Florida, United States
Quantum Laboratories, Inc.
Pompano Beach, Florida, United States
Parkinson's Disease Treatment Center of Southwest Florida
Port Charlotte, Florida, United States
Start Date
February 10, 2020
Primary Completion Date
April 26, 2022
Completion Date
April 26, 2022
Last Updated
January 14, 2025
NCT06793995
NCT05240339
Lead Sponsor
ACADIA Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions